Why Compass Pathways (CMPS) is a 5-bagger: $210/share Thomas George·October 9, 2020Grizzle outlines the structural share price upside of Compass Pathways and its psilocybin drug: COMP 360 to treat...Psychedelics·4 Comments·
The Most Anticipated Psychedelic IPO: Compass Pathways (CMPS) Thomas George·September 18, 2020Grizzle sits down with Terry Chong (Partner, Grizzle Venture) to discuss one of the most anticipated psychedelic IPOs:...Psychedelics·3 Comments·
Psychedelics: Interview with MindMed (MMED) CEO JR Rahn Thomas George·May 6, 2020Psychedelics·1 Comment·
Psychedelics: Valuing MindMed (MMED) Thomas George·March 13, 2020Thomas George and Terry Chong examine the approval FDA drug approval process and the valuation of MindMed (MMED)...Psychedelics·0 Comments·
Psychedelics: Cures, Charlatans & MindMed (MMED) Thomas George·March 6, 2020The first episode of the Grizzle Psychedelics series examines the potential of psychedelics to treat addiction & depression...Psychedelics·1 Comment·
New Zealand Researchers Gain Approval for LSD Microdosing Trial Martin Green·November 28, 2019Researchers at the University of Auckland have been given the green light to study the effects of microdosing...Psychedelics·1 Comment·
Federal Agency Hosts Discussion on Effects of Psychedelics Martin Green·November 27, 2019The National Institute of Mental Health is hosting a talk on the neuropharmacology of psilocybin (aka magic mushrooms)...Psychedelics·0 Comments·
